We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Genetic Test Would Help Cut Bowel Cancer Spread

By LabMedica International staff writers
Posted on 15 Oct 2014
Print article
Image: Histopathology of non-polyposis colorectal cancer or Lynch Syndrome (Photo courtesy of Dr. L. Marcucci MD).
Image: Histopathology of non-polyposis colorectal cancer or Lynch Syndrome (Photo courtesy of Dr. L. Marcucci MD).
Screening families of patients with bowel cancer for a genetic condition would cut their risk of developing bowel, womb, and ovarian cancers.

Lynch syndrome (LS) is an inherited autosomal dominant disorder characterized by an increased risk of colorectal cancer (CRC) and other cancers, and caused by mutations in the DNA mismatch repair genes.

Scientists at the University of Exeter Medical School (UK) and Cardiff University (UK) evaluated the accuracy and cost-effectiveness of strategies to identify LS in newly diagnosed early-onset CRC patients who were less than 50 years of age. Cascade testing of relatives is employed in all strategies for individuals in whom LS was identified. The investigators conducted systematic reviews of the test accuracy of microsatellite instability (MSI) testing or immunohistochemistry (IHC) in individuals with CRC at risk of LS, and of economic evidence relating to diagnostic strategies for LS.

The team identified and assessed 42 studies in total, before constructing a computer model of screening strategies for Lynch Syndrome. These were of mixed quality, with significant methodological concerns identified for most. IHC and MSI can both play a part in diagnosing LS but neither is gold standard. The maximum health benefit to the population of interest would be obtained using universal germline testing, but this would not be cost-effective.

The findings indicate that screening the 1,700 people under the age of 50 who are newly diagnosed with bowel cancer each year would identify two thirds of these whose cancer was caused by Lynch Syndrome. From this group, the findings suggest that 40 further cases of cancer could be avoided in them and their relatives. The team used the same model to estimate that 28 cancer related deaths, 24 from bowel cancer and four from womb cancer, could be prevented each year if Lynch Syndrome screening for people with bowel cancer was introduced.

Ian Frayling, PhD, MRCPath, a senior coauthor, said, “If Lynch Syndrome is identified as the cause of bowel cancer, patients can be offered risk-reducing measures such as more intensive postoperative colonoscopy surveillance to spot recurrences and new cancers early. As close relatives have a 50% chance of sharing the gene, screening would provide a valuable opportunity to detect the condition in children, siblings, parents and more distant relatives. It would mean measures could be taken to reduce the risk of cancers developing.” The study was published in the September 2014 issue of the journal Health Technology Assessment.

Related Links:

University of Exeter Medical School 
Cardiff University


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Vaginitis Test
Allplex Vaginitis Screening Assay
New
Dermatophytosis Rapid Diagnostic Kit
StrongStep Dermatophytosis Diagnostic Kit

Print article

Channels

Molecular Diagnostics

view channel
Image: The study investigated D-dimer testing in patients who are at higher risk of pulmonary embolism (Photo courtesy of Adobe Stock)

D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism

Pulmonary embolism (PE) is a commonly suspected condition in emergency departments (EDs) and can be life-threatening if not diagnosed correctly. Achieving an accurate diagnosis is vital for providing effective... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.